Pranil Balasaheb Toraskar

Pranil Balasaheb Toraskar

Auto-generated profile, based on publicly available information

Pranil Balasaheb Toraskar

Dr. J. J. Magdum Pharmacy College, Jaysingpur, Maharashtra, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2026 in Current Advances in Medicine
Verified
Journal Article
Closed access
PDF file
PTPranil Toraskar
Pranil Toraskar
PPPravin Pawar
Pravin Pawar
VPVrushabh Patil
Vrushabh Patil
SPShitalkumar Patil
Shitalkumar Patil
Introduction: Diabetic retinopathy and inherited retinal dystrophies cause significant vision impairment globally and are grouped under ocular retinopathies. While traditional therapies are less effective as they only offer symptomatic relief, they run the risk of the disease progressing even further. The advent of the CRISPR-Cas9 gene editing system has the potential to allow the direct disease modification and correction of the diseased state of the gene. Therefore, a paradigm shift can occur where traditional therapies only offer symptomatic relief and disease modification can be offered instead. The objective of this article is to describe the current state of CRISPR-Cas9 for ocular retinopathies from the perspective of disease modification, and incorporate potential barriers to design a framework to assess the future opportunities and obstacles to the CRISPR-Cas9 gene editing system in the clinic. Methods: CRISPR 'Cas9', retinal 'gene editing', 'inherited retinal diseases', 'delivery systems', and a combination of these terms were employed when searching published literature. Studies were published in English, were original research, reviews, or clinical trials, and were peer-reviewed. Studies were excluded if they were not related to the ocular applications of CRISPR. Results: Results from pre-clinical studies or early-stage trials indicate that CRISPR-Cas9 may be used to restore the function of diseased retina and stabilize the further progression of the disease. Delivery systems are becoming more efficient and less likely to elicit immune responses. The expected therapeutic result is higher when all these systems are combined. Next-generation CRISPR editors, together with AI-based RNA design and delivery systems, are expected to improve the editing of the 'epigenome'. Discussion: The combination of CRISPR-Cas9 with cell-based therapies and personalized medicine approaches will continue to improve the precision and effectiveness of a given treatment. Advanced technologies in the field of gene modification and editing, AI-guided RNA therapies, and epigenome editing continue to remove obstacles related to specificity and expand the treatable areas in medicine. Conclusion: The potential of CRISPR-Cas9 in the treatment of Ocular Retinopathies is high given its ability to treat diseases by repairing their genetic causes. Continued off-target and delivery challenges and the slow pace of regulations will hinder the privileged work of multidisciplinary teams that are focused on the potential of CRISPR technologies. The long-term restoration of vision to patients who suffer from Retinal Diseases and improving their vision is not only the goal, but one of the more certain outcomes of this work.

17 March 2026 in Journal of International Research in Medical and Pharmaceutical Sciences
Verified
Journal Article
Closed access
SVShraddha Pravin Vashikar
Shraddha Pravin Vashikar
SCSatvik Rahul Chavan
Satvik Rahul Chavan
SPShubham Bhauso Patil
Shubham Bhauso Patil
PTPranil Balasaheb Toraskar
Pranil Balasaheb Toraskar
VPVrushabh Sunil Patil
Vrushabh Sunil Patil
Background: Topical ocular therapy is dominated by eye drops, yet drug delivery to ocular tissues is frequently inefficient because of rapid tear dilution, blinking, nasolacrimal drainage, and layered anatomical barriers. These limitations can lead to low bioavailability, frequent dosing, variable clinical response, and avoidable systemic exposure. Stimuli-responsive in situ gels and drug nanocarriers have each been developed to address parts of this problem, motivating integrated “nano-in-gel” systems. Objective: To summarize and critically analyze nanoparticle-laden in situ ophthalmic gels as precision drug-delivery platforms for anterior and posterior segment diseases, focusing on design rationale, materials, performance outcomes, and translational barriers. Method: This narrative review synthesizes peer-reviewed research on ophthalmic in situ gelling systems (thermo-, pH-, and ion-activated) and nanocarriers (polymeric nanoparticles, lipid nanoparticles, liposomes, micelles, dendrimers, and nanogels), with emphasis on hybrid formulations in which nanoparticles are dispersed within an in situ gelling matrix. Key formulation variables, characterization methods, and in vitro/ex vivo/in vivo evaluation approaches are summarized. Results: Across reported studies, nanoparticle-laden in situ gels consistently improve precorneal residence time and enable sustained drug release, often translating into higher corneal permeation and enhanced pharmacodynamic effects in models of glaucoma, keratitis, dry eye disease, and ocular inflammation. Performance is driven by dual mechanisms: gel-mediated retention and nanoparticle-mediated protection, solubilization, and controlled release. However, clinical translation is constrained by sterilization compatibility, long-term stability, scalable manufacturing, and regulatory complexity for combination products. Conclusion: Nanoparticle-laden in situ gels are promising, adaptable platforms that can reduce dosing burden and improve ocular exposure, but progress to routine clinical use will depend on robust quality-by-design development, standardized characterization, and clinically relevant safety and efficacy validation.